Amsbio adds experimental cell lines to CAR-T services lineup

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Meletios Verras)
(Image: Getty/Meletios Verras)

Related tags: CAR-T, Research, Cell line development, Cell lines, Contract research

Amsbio is adding experimental cell lines to its CAR-T cell services to meet an increasing demand for the technology, according to the UK-based provider.

According to Amsbio, the US Food and Drug Administration's (FDA) approval​ of Chimeric Antigen Receptor (CAR) T-cells for the treatment of leukemia and lymphoma has created a demand for the technology in research.

A spokesperson for Amsbio told us that, because of the growth in research for the therapeutic uses of CAR T-cells, “Amsbio has a growing list (e.g. BCMA, CD123, PMSA) of experimental cell lines, recombinant proteins, and screening services to advance the search for new CAR T-cell therapies.”

The spokesperson explained that the first FDA approved treatments for CAR-T were cells directed against B cell protein CD19 targets. This approval led to research identifying additional targets for blood cancers and solid tumors.

Each cell line added to Amsbio’s offering was selected because of the different levels of protein in the cell lines to mimic different stages of cancer target cells protein expression.

Amsbio’s experimental cell lines include stable CHO recombinant cell lines, which can be used to express full-length human CD123, PSMA, and ICOSL. Each new clonal cell line was selected for different levels of expression to mimic different stages of cancer target cells with varying levels of CD123, PSMA, and ICOSL.

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars